Ernexa Therapeutics Stock Forecast
NASDAQ: ERNAHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ERNA analyst consensus
Consensus (1 analysts)
none
Avg. price target
$30.00+1104.82%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 1 Wall Street analyst covering Ernexa Therapeutics (2026-10-09), 1 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $30.00, with a high estimate of $30.00 and a low estimate of $30.00. The average target implies upside of 1104.8% from the current price of $2.49.
The spread between the highest and lowest targets is 0.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ERNA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 1 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $30.00 | +1104.82% |
| Average target | $30.00 | +1104.82% |
| High target | $30.00 | +1104.82% |
How analysts view Ernexa Therapeutics's peers
| Company | Consensus | Price | Avg. target | Implied move |
|---|---|---|---|---|
| GRI | none | 1.68 | $18.50 | +1001.19% |